![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_v-wiNyh38Azshn53jvScL1ro8zrZVgAh8xFWxuWVrjmCgD5qxDdZ2Dhcq0zcogZf2wt6DwPyJeFcqrpDerbDmF2IQ1Nzm4rAJVfomTGg8=s0-d){kind=small}
Public release date: 15-Dec-2011[ | E-mail |
Share ] Contact: Judy Romero
646-434-4608
Cardiovascular Research Foundation
Top scientists gather for meeting on ground-breaking advances and pioneering innovations in cell-based therapeutic approaches to cardiovascular diseases
WHAT:
The Seventh International Conference on Cell Therapy for Cardiovascular Disease is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on preclinical and clinical studies on the path to commercialization, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.
WHY:
Now in its 11th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.
WHO:
Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.
WHEN:
January 25-27, 2012
WHERE:
Vivian and Seymour Milstein Family Heart Center
New York, NY
###
For more information visit: http://celltherapy.crf.org/
HOW TO REGISTER:
Media may apply for registration by contacting Judy Romero at 646-434-46008 or jromero@crf.org.
About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs, and therapies in the subspecialty of interventional cardiology and endovascular medicine.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 15-Dec-2011[ | E-mail |
Share ] Contact: Judy Romero
646-434-4608
Cardiovascular Research Foundation
Top scientists gather for meeting on ground-breaking advances and pioneering innovations in cell-based therapeutic approaches to cardiovascular diseases
WHAT:
The Seventh International Conference on Cell Therapy for Cardiovascular Disease is a one-and-a-half day comprehensive program dedicated to the evolving field of cell-based therapies for the repair and regeneration of cardiac and vascular disease, as well as related diseases such as diabetes and stroke. This year's conference will focus on preclinical and clinical studies on the path to commercialization, highlighting the status of molecular, cell, and tissue products in addition to delivery systems.
WHY:
Now in its 11th year of clinical trials, the application of stem cells in the treatment of cardiovascular diseases has seen many notable successes, as well as identified challenges that await the next round of clinical studies. Leaders in the field will convene to present their work, experiences, observations, and opinions on the benefits and unmet challenges of cell-based therapies.
WHO:
Warren Sherman, MD, Course Director, is Director of Cardiac Cell-Based Endovascular Therapies at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Sherman is a renowned clinical investigator in the field of myocardial regeneration who pioneered a technique for injecting stem cells into the heart. In Rotterdam in May 2001, he performed the first catheter-based injection of stem cells into the heart of a patient with congestive heart failure due to a previous heart attack. At Columbia University Medical Center, researchers led by Dr. Sherman are using the patient's own myoblasts -- progenitor cells found in muscle -- to repair and replace injured cardiac tissue in a process called myogenesis. Dr. Sherman collaborates in studies to improve the outcomes of cell implantation with colleagues at Columbia University Medical Center, all of whom will be presenting their research at the conference.
WHEN:
January 25-27, 2012
WHERE:
Vivian and Seymour Milstein Family Heart Center
New York, NY
###
For more information visit: http://celltherapy.crf.org/
HOW TO REGISTER:
Media may apply for registration by contacting Judy Romero at 646-434-46008 or jromero@crf.org.
About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies, drugs, and therapies in the subspecialty of interventional cardiology and endovascular medicine.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2011-12/crf-gco121511.php
nba lockout news nba lockout news gifts for mom gifts for mom pepper spray storage auctions storage auctions
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.